Spero Therap

SPRO

----

Current ValuationThe current P/E ratio is 9.39, within the reasonable range, cheaper than 22.76% of the time in the past 3 years, and the industry ranks 28/602, the industry Median -2.15.

9.39xP/E

Stock price$1.19Earnings per share$0.13

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	14.49x	68.35%	$23.37B
GRFSUSGRIFOLS SA	9.58x	42.44%	$5.03B
ACADUSAcadia Pharma	9.03x	73.45%	$3.44B
PURRUSHyperliquid Strategies	9.18x	84.74%	$2.35B
ADMAUSAdma Biologics	12.89x	35.42%	$2.18B
AUPHUSAurinia Pharma	6.71x	54.40%	$2.11B
LKFTUSLakefront Biotherapeutics	2.76x	86.19%	$1.91B
ANABUSAnaptysbio	5.54x	1,003.56%	$1.45B
VORUSVor BioPharma	1.76x	89.77%	$1.11B
MGTXUSMeiraGTx	13.12x	122.03%	$1.04B
RIGLUSRigel Pharma	2.74x	83.91%	$880.76M
ABUSUSArbutus Pharma	5.73x	533.09%	$876.38M
BVNRYUSBavarian Nordic A/S	3.42x	--	$820.28M
IRWDUSIronwood Pharma	4.63x	715.55%	$601.47M
AGENUSAgenus	4.10x	--	$376.37M
CUVLUSClinuvel Pharmaceuticals	13.27x	--	$304.08M
QTTBUSQ32 Bio	7.25x	162.67%	$245.00M
CGENUSCompugen	6.22x	173.68%	$218.81M
PLXUSProtalix Biotherap	11.53x	400.00%	$218.35M
VXRTUSVaxart	2.75x	328.57%	$106.28M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.